Mechanistic description
Amyloid PET normalizes faster than CSF p-tau217 due to differential compartment kinetics (vascular vs. neuronal). Using amyloid PET alone for stopping may prematurely halt treatment before downstream tau pathology resolution. This hypothesis remains biologically plausible but lacks outcome validation—the clinical inference (dual threshold required) is not yet supported by data showing harm from amyloid-PET-only stopping.
Mechanism / pathway
- NA - Biomarker validation hypothesis
- neurodegeneration
Evidence for (7)
PET SUVr normalizes within 12-18 months in most donanemab responders; p-tau217 shows ongoing decline beyond 24 months
Preclinical models show Aβ clearance precedes tau pathology resolution by months
The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.
CSF markers of vascular injury correlate with tau and cognitive decline in early Alzheimer's disease.
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease.
Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias.
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.
Evidence against (2)
No data demonstrates worse outcomes in patients who stopped at amyloid PET negativity
The 'temporal lag' is asserted but not quantified with inter-patient variance data
Evidence matrix
Supporting
- PET SUVr normalizes within 12-18 months in most donanemab responders; p-tau217 shows ongoing decline beyond 24 months PMID:37340743
- Preclinical models show Aβ clearance precedes tau pathology resolution by months PMID:30895603
- The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. PMID:30679382 · 2019 · Science
- CSF markers of vascular injury correlate with tau and cognitive decline in early Alzheimer's disease. PMID:41319164 · 2025 · Alzheimers Dement
- CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease. PMID:33283854 · 2021 · Brain
- Levels of plasma brain-derived tau and p-tau181 in Alzheimer's disease and rapidly progressive dementias. PMID:37858957 · 2024 · Alzheimers Dement
- Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. PMID:34310832 · 2022 · Alzheimers Dement
Contradicting
- No data demonstrates worse outcomes in patients who stopped at amyloid PET negativity PMID:38042029
- The 'temporal lag' is asserted but not quantified with inter-patient variance data PMID:NA
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Temporal Decoupling of CSF p-tau217 Normalization from Amyloid PET Negativity C…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-793f9f273d
@misc{scidex_hypothesis_h793f9f2,
title = {Temporal Decoupling of CSF p-tau217 Normalization from Amyloid PET Negativity C…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-793f9f273d},
note = {SciDEX artifact hypothesis:h-793f9f273d}
}